{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:58:34Z","timestamp":1777633114906,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The pharmacokinetics\/tolerability of lanreotide Autogel have been evaluated. Healthy volunteers (n = 24) first received immediate-release lanreotide as a single subcutaneous (s.c.) injection. After two days, 40 or 60 mg lanreotide Autogel was injected subcutaneously. Blood was sampled at various intervals for 56 days. Systemic\/local adverse events and changes in biological profile\/vital signs were recorded. Lanreotide Autogel produced a prolonged-release pharmacokinetic profile: mean area under the serum concentration-time curve from time 0 to infinity (AUC) was 53.73 + 8.99 and 79.48 + 13.06 ng mL\u22121 day for 40 and 60 mg, respectively, mean peak serum concentration (Cmax) was 4.38 + 2.91 and 5.71 + 3.52 ng mL\u22121, respectively, median time to reach Cmax (minimum-maximum) was 0.50 (0.083\u201318.0) and 0.38 (0.083\u20139.01) days, respectively, mean apparent elimination half-life was 21.63 + 9.42 and 22.01 + 9.87 days, respectively, and relative bioavailability was 0.93 + 0.12 and 0.82 + 0.15, respectively. Thus, lanreotide Autogel exhibited linear pharmacokinetics for the doses studied. Pharmacokinetic profiles were similar in both genders, apart from statistically significant differences in Cmax and Cmax\/AUC. The Autogel formulation of lanreotide was well tolerated, with systemic adverse events being mild\/moderate. Erythema and a painless subcutaneous induration were the most common local adverse events. Lanreotide Autogel provided a prolonged dosing interval and good tolerability for treating acromegaly and carcinoid syndrome.<\/jats:p>","DOI":"10.1211\/0022357023123","type":"journal-article","created":{"date-parts":[[2004,4,6]],"date-time":"2004-04-06T23:28:53Z","timestamp":1081294133000},"page":"471-476","source":"Crossref","is-referenced-by-count":42,"title":["Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers"],"prefix":"10.1093","volume":"56","author":[{"given":"R M","family":"Antonijoan","sequence":"first","affiliation":[{"name":"Centre d'Investigaci\u00f3 de Medicaments, Institute of Research, Servei de Farmacologia Cl\u00ednica, Hospital of Santa Creu and Sant Pau, Departament de Farmacologia i Terap\u00e8utica , UAB Barcelona,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J","family":"Barbanoj","sequence":"additional","affiliation":[{"name":"Centre d'Investigaci\u00f3 de Medicaments, Institute of Research, Servei de Farmacologia Cl\u00ednica, Hospital of Santa Creu and Sant Pau, Departament de Farmacologia i Terap\u00e8utica , UAB Barcelona,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"Cordero","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics , Ipsen Pharma SA, Barcelona,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Peraire","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics , Ipsen Pharma SA, Barcelona,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Obach","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics , Ipsen Pharma SA, Barcelona,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Vall\u00e8s","sequence":"additional","affiliation":[{"name":"Medical Department , Ipsen Pharma SA, Barcelona,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"CheZ\u00e9rif-Cheikh","sequence":"additional","affiliation":[{"name":"Ipsen Pharma SA , Sant Feliu de Llobregat, Barcelona,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M-L","family":"Torres","sequence":"additional","affiliation":[{"name":"Ipsen Pharma SA , Sant Feliu de Llobregat, Barcelona,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Bismuth","sequence":"additional","affiliation":[{"name":"Ipsen Pharma SA , Sant Feliu de Llobregat, Barcelona,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Montes","sequence":"additional","affiliation":[{"name":"Ipsen Pharma SA , Sant Feliu de Llobregat, Barcelona,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,4,1]]},"reference":[{"key":"2024103109410737600_cit1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2265.1980.tb03135.x","article-title":"Epidemiology of acromegaly in the Newcastle region","volume":"12","author":"Alexander","year":"1980","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"2024103109410737600_cit2","first-page":"4099","article-title":"Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)","volume":"85","author":"Baldelli","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2024103109410737600_cit3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0009-9236(99)70011-1","article-title":"Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency","volume":"66","author":"Barbanoj","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103109410737600_cit4","first-page":"18","article-title":"Three-year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide","volume":"82","author":"Caron","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2024103109410737600_cit5","first-page":"P47","article-title":"Lanreotide Autogel in acromegaly: a pharmacokinetic and pharmacodynamic analysis","volume":"6","author":"Cendros","year":"2003","journal-title":"Endocr. Abs."},{"key":"2024103109410737600_cit6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1023\/A:1009961116472","article-title":"Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly","volume":"2","author":"Chanson","year":"2000","journal-title":"Pituitary"},{"key":"2024103109410737600_cit7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/BF03345477","article-title":"Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly","volume":"22","author":"Colao","year":"1999","journal-title":"J. Endocrinol. Invest."},{"key":"2024103109410737600_cit8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/0003-4819-117-9-711","article-title":"Octreotide treatment of acromegaly. A randomized, multicenter study","volume":"117","author":"Ezzat","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"2024103109410737600_cit9","first-page":"526","article-title":"Traitement de l'acrom\u00e9galie par une forme de lib\u00e9ration prolong\u00e9e du lanr\u00e9otide. Un nouvel analogue de la somatostatine","volume":"22","author":"Heron","year":"1993","journal-title":"Presse M\u00e9d."},{"key":"2024103109410737600_cit10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-112-3-173","article-title":"Therapeutic efficacy of the somatostatin analog SMS 201\u2013995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety","volume":"112","author":"Ho","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"2024103109410737600_cit11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/eje.0.1300229","article-title":"Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly","volume":"130","author":"Johnson","year":"1994","journal-title":"Eur. J. Endocrinol."},{"key":"2024103109410737600_cit12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1210\/endo-83-4-783","article-title":"Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro","volume":"83","author":"Krulich","year":"1968","journal-title":"Endocrinology"},{"key":"2024103109410737600_cit13","doi-asserted-by":"crossref","DOI":"10.1137\/1.9781611970852","volume-title":"Analytical and numerical methods for Volterra equations.","author":"Linz","year":"1985"},{"key":"2024103109410737600_cit14","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors","volume":"340","author":"Kulke","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"2024103109410737600_cit15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/edrv-4-3-271","article-title":"Pathophysiology of acromegaly","volume":"4","author":"Melmed","year":"1983","journal-title":"Endocr. Rev."},{"key":"2024103109410737600_cit16","first-page":"145","article-title":"Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide","volume":"79","author":"Morange","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2024103109410737600_cit17","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O'Toole","year":"2000","journal-title":"Cancer"},{"key":"2024103109410737600_cit18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1210\/jcem-71-2-391","article-title":"Long term effect of incremental doses of the somatostatin analog SMS 201\u2013995 in 58 acromegalic patients. French SMS 201\u2013995 approximately equal to Acromegaly Study Group","volume":"71","author":"Sassolas","year":"1990","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2024103109410737600_cit19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/bmj.286.6362.330","article-title":"Treatment of acromegaly","volume":"286","author":"Thomas","year":"1983","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"2024103109410737600_cit20","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1200\/JCO.1999.17.4.1111","article-title":"Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms","volume":"17","author":"Wymenga","year":"1999","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1211%2F0022357023123","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/56\/4\/471\/60261003\/0022357023123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/56\/4\/471\/60261003\/0022357023123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:23:17Z","timestamp":1730370197000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/56\/4\/471\/6147241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,1]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2004,4,1]]},"published-print":{"date-parts":[[2004,4,1]]}},"URL":"https:\/\/doi.org\/10.1211\/0022357023123","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,4]]},"published":{"date-parts":[[2004,4,1]]}}}